Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2-positive Carcinoma of Breast”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT06977893
What this trial is testing

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Who this might be right for
HR+/HER2- Breast Cancer
First Affiliated Hospital of Zhejiang University 194
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07691333
What this trial is testing

Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer

Who this might be right for
HR+/HER2- Breast CancerBreast Neoplasms
Fujian Cancer Hospital 35
Testing effectiveness (Phase 2)Active Not RecruitingNCT05826964
What this trial is testing

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Who this might be right for
Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+1 more
University of Miami 24
Testing effectiveness (Phase 2)Looking for participantsNCT05900206
What this trial is testing

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
Karolinska University Hospital 370
Testing effectiveness (Phase 2)Study completedNCT00629616
What this trial is testing

Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer

Who this might be right for
Breast Cancer
UNICANCER 116
Not applicableStudy completedNCT04001634
What this trial is testing

Dual Anti-HER2 Therapy (Lapatinib and Trastuzumab) Plus Chemotherapy in HER2-positive MBC

Who this might be right for
Breast Cancer
Fudan University 285
Testing effectiveness (Phase 2)UnknownNCT03876587
What this trial is testing

Pyrotinib Combined With Docetaxel in the First-line Treatment of HER2-positive MBC

Who this might be right for
Metastatic Breast Cancer
Zhejiang Cancer Hospital 79
Not applicableUnknownNCT03728829
What this trial is testing

Targeted Next Generation Sequencing for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Breast Cancer

Who this might be right for
ObservationalProspective
Hebei Medical University Fourth Hospital 100
Early research (Phase 1)Study completedNCT03207529
What this trial is testing

Alpelisib and Enzalutamide in Treating Patients With Androgen Receptor and PTEN Positive Metastatic Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+15 more
M.D. Anderson Cancer Center 18
Testing effectiveness (Phase 2)Study completedNCT02260531
What this trial is testing

Cabozantinib +/- Trastuzumab In Breast Cancer Patients w/ Brain Metastases

Who this might be right for
Breast CancerBrain Tumor - Metastatic
Dana-Farber Cancer Institute 36
Not applicableUnknownNCT03979339
What this trial is testing

Feasibility of a New Technology for Isolating Circulating Tumour Cells

Who this might be right for
HER2-positive Metastatic Breast CancerOvarian CancerHormone-resistant Prostate Cancer+1 more
Centre Oscar Lambret 76
Not applicableWithdrawnNCT00898573
What this trial is testing

Lapatinib Resistance in Patients With Breast Cancer

Who this might be right for
Breast Cancer
Case Comprehensive Cancer Center
Large-scale testing (Phase 3)Active Not RecruitingNCT02568839
What this trial is testing

Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer

Who this might be right for
Early-Stage Breast CarcinomaHER-2 Positive Breast Cancer
Thomas Hatschek 202
Large-scale testing (Phase 3)Active Not RecruitingNCT06316531
What this trial is testing

A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 274
Not applicableLooking for participantsNCT06693037
What this trial is testing

Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy

Who this might be right for
HER2-positive Breast Cancer
Shu Wang 2,092
Testing effectiveness (Phase 2)Ended earlyNCT04251169
What this trial is testing

Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression

Who this might be right for
Metastatic Breast Cancer
SOLTI Breast Cancer Research Group 20
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Not applicableStudy completedNCT05572645
What this trial is testing

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Who this might be right for
Breast Cancer
Fudan University 333
Post-approval studies (Phase 4)UnknownNCT05131841
What this trial is testing

Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

Who this might be right for
Metastatic Breast Cancer
Zhejiang Cancer Hospital 60
Testing effectiveness (Phase 2)UnknownNCT03919253
What this trial is testing

Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study

Who this might be right for
HER2-positive Breast Cancer
Hebei Medical University Fourth Hospital 80
Next Page